ArticleAlimentary pharmacology & therapeutics2019
Faecal microbiota transplant decreases mortality in severe and fulminant Clostridioides difficile infection in critically ill patients.
Article in Alimentary pharmacology & therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Systematic Review with Meta-Analysis: Fecal Microbiota Transplantation for Severe or Fulminant Clostridioides difficile.Digestive diseases and sciences · 2022Pooled it
- Fecal Microbiota Transplantation in 2025: Two Steps Forward, One Step Back.Current gastroenterology reports · 2026Review
- Antimicrobial Resistance: The Answers.British journal of biomedical science · 2026Review
- Gastrointestinal complications in intensive care.Medical review (2021) · 2025Review
- Outcomes of Fecal Microbiota Transplantation forOpen forum infectious diseases · 2025Article
- What's New and What's Next in Fecal Microbiota Transplantation?Biologics : targets & therapy · 2025Review
- Fecal microbiota transplantation: current challenges and future landscapes.Clinical microbiology reviews · 2024Review
- Safety and efficacy of fecal microbiota transplantation (FMT) as a modern adjuvant therapy in various diseases and disorders: a comprehensive literature review.Frontiers in immunology · 2024Review
- Fecal Microbiota Transplantation.Clinics in colon and rectal surgery · 2023Review
- Article
- Review
- Fecal Microbiota Transplantation for Severe or FulminantJournal of the Canadian Association of Gastroenterology · 2022Article
- Successful use of early, repeat fecal microbiota transplantation for initial treatment of severe, refractory Clostridioides difficile colitis.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2021Article
- Diagnosis and management of Clostridioides difficile infection in patients with inflammatory bowel disease.Current opinion in gastroenterology · 2021Review
- Hospitalized Older Patients withAdvances in geriatric medicine and research · 2021Article
- Fecal Microbiota Transplantation for Clostridioides difficile in High-Risk Older Adults Is Associated with Early Recurrence.Digestive diseases and sciences · 2020Article
- Physician and patient perceptions of fecal microbiota transplant for recurrent or refractoryJGH open : an open access journal of gastroenterology and hepatology · 2020Article
- Functional profile of host microbiome indicatesGut microbesArticle
Corrections and comments
- Commented on by
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundSevere and fulminant Clostridioides difficile infection is associated with high mortality rates. While faecal microbiota transplant has been shown to be effective for recurrent C difficile infection, there is little data on the utility of faecal microbiota transplant in severe or fulminant C difficile infection.
aimTo compare the outcomes of antibiotics and faecal microbiota transplantation vs antibiotics alone (standard of care) in critically ill patients with severe or fulminant C difficile infection.
methodsThis was a retrospective, matched cohort study in one urban tertiary academic care centre including 48 patients hospitalised with severe or fulminant C difficile infection who required care in intensive care unit.
resultsPatients who received faecal microbiota transplantation (n = 16) had a 77% decrease in odds for mortality (OR 0.23, 95% CI 0.06-0.97) with a number needed to treat of 3 to prevent one death.
conclusionsFaecal microbiota transplantation provides mortality benefit over standard of care for severe and fulminant C difficile infection and should be considered in critically ill patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.